Eravacycline (TP-434) (Synonyms: TP-434) |
| Catalog No.GC32188 |
Eravaciclina (TP-434) es un agente antibacteriano potente y de amplio espectro.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1207283-85-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Eravacycline (TP-434) is a novel tetracycline (TET) antibiotic. It exhibits in vitro activity against various gram-positive, gram-negative aerobic and anaerobic pathogens, including those exhibiting TET-specific acquired resistance mechanisms[1]. It inhibits protein synthesis through binding to the 30S ribosomal subunit[2]. Eravacycline (TP-434) was approved for the treatment of complicated intraabdominal infections (cIAIs) in adults[3-4].
Eravacycline (TP-434) (0.03 to 4 μg/ml; 24h) showed obvious bacteriostatic effect on pre-established biofilms formed by a uropathogenic Escherichia coli strain in vitro[5]. Eravacycline (0-8 μg/ml) has antibacterial activity against a large panel of clinical M. abscessus isolates in vitro[6].
Eravacycline (3-12mg/kg) was injected intravenically through the tail vein 2 and 12 h after infection with tetracycline resistant Streptococcus pneumoniae and MRSA isolates. Eravacycline has obvious therapeutic effect on infected mice, for lung infections with MRSA SA191, eravacycline given at 10 mg/kg i.v. produced a 2.4 log10 CFU reduction versus the values for the 24-hour untreated controls.[7].
References:
[1]. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Eravacycline. 2019 Apr 10. PMID: 31643186.
[2]. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65(2):232-60 ; second page, table of contents. doi: 10.1128/MMBR.65.2.232-260.2001. PMID: 11381101; PMCID: PMC99026.
[3]. Alosaimy S, Abdul-Mutakabbir JC, et,al. Evaluation of Eravacycline: A Novel Fluorocycline. Pharmacotherapy. 2020 Mar;40(3):221-238. doi: 10.1002/phar.2366. Epub 2020 Feb 21. PMID: 31944332.
[4]. Sutcliffe JA, O'Brien W, et,al. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013 Nov;57(11):5548-58. doi: 10.1128/AAC.01288-13. Epub 2013 Aug 26. PMID: 23979750; PMCID: PMC3811277.[5]. Grossman TH, O'Brien W, et,al. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Antimicrob Agents Chemother. 2015 Apr;59(4):2446-9. doi: 10.1128/AAC.04967-14. Epub 2015 Jan 26. PMID: 25624334; PMCID: PMC4356792.
[6]. Li A, He S, et,al. Omadacycline, Eravacycline, and Tigecycline Express Anti-Mycobacterium abscessus Activity In Vitro. Microbiol Spectr. 2023 Jun 15;11(3):e0071823. doi: 10.1128/spectrum.00718-23. Epub 2023 May 4. PMID: 37140428; PMCID: PMC10269442.
[7]. Grossman TH, Murphy TM, et,al. Eravacycline (TP-434) is efficacious in animal models of infection. Antimicrob Agents Chemother. 2015 May;59(5):2567-71. doi: 10.1128/AAC.04354-14. Epub 2015 Feb 17. PMID: 25691636; PMCID: PMC4394802.
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *